logo
episode-header-image
Oct 2024
23m 58s

Hot shot: the wider promise of weight-lo...

The Economist
About this episode

First they treated diabetes. Then obesity. Now GLP-1 drugs are being tested on a range of other diseases too. Though the US economy is roaring, many Americans are glum about its prospects. How could that affect the election (9:02)? And our podcast on why Chinese migrants are making perilous journeys through the jungle to reach America (16:55).


Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+


For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. 




Hosted on Acast. See acast.com/privacy for more information.

Up next
Today
Islamism in Britain: what is the threat?
Though a growing share of the British population is anxious about Islam, they have no reason to be. Islamism, a fringe ideology that believes government and society should be guided by Islamic principles, is the real concern. America cracks down on multinationals’ efforts to shif ... Show More
23m 41s
Yesterday
Strait and narrowing: the Houthis’ striking advance
After years of stalemate, Yemen’s Iran-backed Houthis are taking territory, including on a Red Sea strait. We ask what has changed, and how the shift fits into the wider regional conflict. As America’s midterm elections approach, we examine the fragmentation of the coalition that ... Show More
22m 46s
Sep 12
The Weekend Intelligence: Shire folk
For 15 years, the British media dismissed Tommy Robinson as a far-right extremist. We kept him off our televisions, and out of our newspapers. Today his rallies attract tens of thousands of followers and he has the ear of the world’s richest man.Shire Folk is the story of how som ... Show More
49m 13s
Recommended Episodes
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Dec 2024
A checkup on weight-loss drugs
What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ... Show More
20m 17s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Nov 2025
The end of dieting
The Trump administration is making GLP-1s more affordable. This class of drugs seems to have forever changed the game on diet and exercise for Americans. This episode was produced by Miles Bryan, edited by Jolie Myers, fact-checked by Laura Bullard, engineered by Patrick Boyd and ... Show More
25m 50s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s